Related Experiment Video
Updated: May 22, 2025
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
Published on: February 23, 2024
A Caspase-3 responsive nanoemulsion for targeted treatment of rheumatoid arthritis through dual modulation of
Jia Zhang1, Xianbao Shi2, Zhuo Wu3
1Department of hematology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China.
Abstract:
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation, pain, and progressive joint damage. Current treatments, while effective, are limited by their potential side effects, particularly in long-term use. This study introduces a novel nanoemulsion-based therapeutic approach combining rapamycin, an mTOR inhibitor, with SS31, a mitochondrial-targeting antioxidant peptide. The rapamycin-SS31 conjugate (RS31) is encapsulated within a nanoemulsion (RS31@NEs) designed to selectively release its components in response to elevated Caspase-3 levels, prevalent in inflamed joints. In vitro and in vivo studies using zymosan-induced arthritis (ZIA) and collagen-induced arthritis (CIA) mouse models demonstrated that RS31@NEs effectively reduced pro-inflammatory cytokines, mitigated oxidative stress, and improved immune modulation by enhancing regulatory T and B cell functions. These findings highlight RS31@NEs as a promising dual-action therapy for RA, combining anti-inflammatory and mitochondrial protective effects while minimizing systemic toxicity.
Insights
This study presents a new nanoemulsion therapy for rheumatoid arthritis (RA) combining rapamycin and SS31. The treatment reduces inflammation and oxidative stress, offering a promising dual-action approach for RA patients.
Area of Science:
- Immunology
- Nanotechnology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
- Current RA treatments have limitations due to potential long-term side effects.
- There is a need for novel therapeutic strategies with improved efficacy and safety profiles.
Purpose of the Study:
- To develop and evaluate a novel nanoemulsion-based therapy (RS31@NEs) for rheumatoid arthritis.
- To combine the anti-inflammatory effects of rapamycin with the mitochondrial protective properties of SS31.
- To create a targeted delivery system for RA treatment that responds to joint inflammation.
Main Methods:
- Rapamycin and SS31 were conjugated (RS31) and encapsulated in a nanoemulsion (RS31@NEs).
- RS31@NEs were designed for targeted release in response to Caspase-3 levels.
- In vitro and in vivo studies were conducted using zymosan-induced arthritis (ZIA) and collagen-induced arthritis (CIA) mouse models.
Main Results:
- RS31@NEs significantly reduced pro-inflammatory cytokines in arthritis models.
- The nanoemulsion effectively mitigated oxidative stress in inflamed joints.
- Enhanced regulatory T and B cell functions were observed, indicating improved immune modulation.
Conclusions:
- RS31@NEs demonstrate a promising dual-action therapeutic potential for rheumatoid arthritis.
- The combination therapy offers both anti-inflammatory and mitochondrial protective benefits.
- Targeted delivery via nanoemulsion may minimize systemic toxicity associated with RA treatment.
More Related Videos
11:03A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
Published on: October 30, 2019
04:49Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF